

Uddannelse & ansættelser:

1987-1998:	Medicin studie på Universitet van Amsterdam, Holland
1999:	Doktorafhandlingen ved Universitet van Amsterdam
1998-2004	Patologiuddannelse ved Academisch Medisch Centrum, Amsterdam
2004-2008	Afdelingslæge, Patologiafdeling, Bispebjerg Hospital og Rigshospitalet.
2008-2013	Overlæge, Patologiafdeling, Rigshospitalet (RH)
2009-nu:	Lektor (C-ektorat) ved Sundhedsvidenskabelig Fakultet, Københavns Universitet.
2013-nu	Klinikkchef Patologiafdeling Rigshospitalet

Publikationsliste

1. High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy. Gromova I, Gromov P, Honma N, Kumar S, Rimm D, Talman ML, **Wielenga VT**, Moreira JM. *Mol Oncol*. 2015 (15)00117-9. [Epub ahead of print]
2. Brask JB, Talman ML, **Wielenga VT**. Neuroendocrine carcinoma of the breast – a pilot study of a Danish population of 240 breast cancer patients. *APMIS*. 2014 Jul;122(7):585-92.
3. Sørensen SD, Greve T, **Wielenga VT**, Wallace WH, Andersen CY. Safety considerations for transplanting cryopreserved ovarian tissue to restore fertility in female patients who have recovered from Ewing's sarcoma. *Future Oncol*. 2014 Feb;10(2):277-83.
4. Brask JB, Talman ML, **Wielenga VT**. Tissue microarray analysis as a screening tool for neuroendocrine carcinoma of the breast. *APMIS*. 2014 Jul;122(7):593-8
5. Greve T, **Wielenga VT**, Grauslund M, Sørensen N, Christiansen DB, Rosendahl M, Yding Andersen C. Ovarian tissue cryopreserved for fertility preservation from patients with Ewing or other sarcomas appear to have no tumour cell contamination. *Eur J cancer*. 2013 May;49(8):1932-8.
6. Gromova I, Gromov P, Kroman N, **Wielenga VT**, Simon R, Sauter G, Moreira JM. Immunoexpression analysis and prognostic value of BLCAP in breast cancer. *PLoS One*. 2012;7(9):e45967.
7. Boedtkjer E, Moreira JMA, Mele M, Vahl P, **Wielenga VT**, Christiansen PM, Jensen VED, Pedersen ST, Aalkjaer C. Contribution of Na⁺,HCO₃⁻-cotransport to cellular pH control in human breast cancer: a role for the breast cancer susceptibility locus NBCn1 (SLC4A7). *Int J Cancer*, accepted.
8. Rossing HH, Talman ML, Laenkholm AV, **Wielenga VT**. Implementation of TMA and digitalization in routine diagnostics of breast pathology. *APMIS*. 2012;120(4):341-7.
9. Kim J, Villadsen R, Sørlie T, Fogh L, Grønlund SZ, Fridriksdottir AJ, Kuhn I, Rank F, **Wielenga VT**, Solvang H, Edwards PA, Børresen-Dale AL, Rønnev-Jessen L, Bissell MJ, Petersen OW. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. *Proc Natl Acad Sci U S A*. 2012;109(16):6124-9.
10. Bernsdorf M, Berthelsen AK, **Wielenga VT**, Kroman N, Teilum D, Binderup T, Tange UB, Andersson M, Kjær A, Loft A, Graff J. Preoperative PET/CT in early-stage breast cancer. *Ann Oncol*. 2012 Feb 21.
11. Rosendahl M, **Timmermans-Wielenga V**, Nedergaard L, Kristensen SG, Ernst E, Rasmussen PE, Anderson M, Schmidt KT, Andersen CY. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. *Fertil Steril*. 2011;95(6):2158-61.
12. Moreira JM, Cabezón T, Gromova I, Gromov P, **Timmermans-Wielenga V**, Machado I, Llombart-Bosch A, Kroman N, Rank F, Celis JE. Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. *Mol Oncol*. 2010;4(6):539-61
13. Gromov P, Gromova I, Friis E, **Timmermans-Wielenga V**, Rank F, Simon R, Sauter G, Moreira JM. Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker. *J Proteome Res*. 2010;9(8):3941-53.
14. de Neergaard M, Kim J, Villadsen R, Fridriksdottir AJ, Rank F, **Timmermans-Wielenga V**, Langerød A, Børresen-Dale AL, Petersen OW, Rønnev-Jessen L. Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment. *Am J Pathol*. 2010;176(3):1229-40.
15. Winther C, **Timmermans-Wielenga V**, Daugaard S, Mortensen SA, Sander K, Andersen CB. Primary cardiac tumors: a clinicopathologic evaluation of four cases. *Cardiovasc Pathol*. 2010;20(1):63-7.
16. Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, **Timmermans-Wielenga V**, Roepstorff P, Rank F, Celis JE. Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. *Mol Oncol*. 2010;4(1):65-89.

17. Li J, Wang K, Li S, **Timmermans-Wielenga V**, Rank F, Wiuf C, Zhang X, Yang H, Bolund L. DNA copy number aberrations in breast cancer by array comparative genomic hybridization. *Genomics Proteomics Bioinformatics*. 2009;7(1-2):13-24.
18. Harboe TL, Eiberg H, Kern P, Ejlertsen B, Nedergaard L, **Timmermans-Wielenga V**, Nielsen IM, Bisgaard ML. A high frequent BRCA1 founder mutation identified in the Greenlandic population. *Fam Cancer*. 2009;8(4):413-9.
19. Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, **Timmermans-Wielenga V**, Iwase T, Akiyama F, Honma N, Rank F. Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort. *Mol Oncol*. 2009;3(3):220-37.
20. Gromov P, Celis JE, Gromova I, Rank F, **Timmermans-Wielenga V**, Moreira JM. A single lysis solution for the analysis of tissue samples by different proteomic technologies. *Mol Oncol*. 2008;2(4):368-79.
21. Li J, Gromov P, Gromova I, Moreira JM, **Timmermans-Wielenga V**, Rank F, Wang K, Li S, Li H, Wiuf C, Yang H, Zhang X, Bolund L, Celis JE. Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis. *Proteomics*. 2008;8(23-24):5038-52.
22. Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirstrom K, Llombart-Bosch A, **Timmermans-Wielenga V**, Rank F, Gromova I. 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. *Mol Cell Proteomics*. 2008;7(10):1795-809.
23. Hansen TV, Ejlertsen B, Albrechtsen A, Bergsten E, Bjerregaard P, Hansen T, Myrholm T, Nielsen PB, **Timmermans-Wielenga V**, Andersen MK, Jønson L, Nielsen FC. A common Greenlandic Inuit BRCA1 RING domain founder mutation. *Breast Cancer Res Treat*. 2009;115(1):69-76.
24. Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, **Timmermans-Wielenga V**, Rank F, Moreira JM. Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. *Mol Oncol*. 2007;1(3):321-49.
25. **Wielenga VJ**, van der Voort R, Taher TE, Smit L, Beuling EA, van Krimpen C, Spaargaren M, Pals ST. Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. *Am J Pathol*. 2000;157(5):1563-73
26. **Wielenga VJ**, van der Neut R, Offerhaus GJ, Pals ST. CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. *Adv Cancer Res*. 2000;77:169-87. Review.
27. Drillenburger P, **Wielenga VJ**, Kramer MH, van Krieken JH, Kluin-Nelemans HC, Hermans J, Heisterkamp S, Noordijk EM, Kluin PM, Pals ST. CD44 expression predicts disease outcome in localized large B cell lymphoma. *Leukemia*. 1999;13(9):1448-55.
28. van der Voort R, Taher TE, **Wielenga VJ**, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, Pals ST. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. *J Biol Chem*. 1999;274(10):6499-506.
29. **Wielenga VJ**, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. *Am J Pathol*. 1999;154(2):515-23.
30. **Wielenga VJ**, van der Voort R, Mulder JW, Kruijff PM, Weidema WF, Oosting J, Seldenrijk CA, van Krimpen C, Offerhaus GJ, Pals ST. CD44 splice variants as prognostic markers in colorectal cancer. *Scand J Gastroenterol*. 1998;33(1):82-7.
31. Mulder JW, **Wielenga VJ**, Pals ST, Offerhaus GJ. p53 and CD44 as clinical markers of tumour progression in colorectal carcinogenesis. *Histochem J*. 1997;29(6):439-52. Review.
32. Montgomery RK, Rings EH, Thompson JF, Schuijt CC, Aras KM, **Wielenga VJ**, Kothe MJ, Büller HA, Grand RJ. Increased C/EBP in fetal rat small intestine precedes initiation of differentiation marker mRNA synthesis. *Am J Physiol*. 1997;272(3 Pt 1):G534-44.
33. Mulder JW, **Wielenga VJ**, Polak MM, van den Berg FM, Adolf GR, Herrlich P, Pals ST, Offerhaus GJ. Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. *Gut*. 1995;36(1):76-80.
34. Griffioen AW, Horst E, Heider KH, **Wielenga VJ**, Adolf GR, Herrlich P, Pals ST. Expression of CD44 splice variants during lymphocyte activation and tumor progression. *Cell Adhes Commun*. 1994;2(3):195-200.
35. **Wielenga VJ**, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. *Cancer Res*. 1993;53(20):4754-6.